B-Cell Chronic Lymphocytic Leukemia with 11q22.3 Rearrangement in Patient with Chronic Myeloid Leukemia Treated with Imatinib.

about

B-Cell Chronic Lymphocytic Leukemia with 11q22.3 Rearrangement in Patient with Chronic Myeloid Leukemia Treated with Imatinib.

Item

http://www.wikidata.org/entity/Q36726837

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

B-Cell Chronic Lymphocytic Leu ...... eukemia Treated with Imatinib.

@ast

B-Cell Chronic Lymphocytic Leu ...... eukemia Treated with Imatinib.

@en

type

Item

label

B-Cell Chronic Lymphocytic Leu ...... eukemia Treated with Imatinib.

@ast

B-Cell Chronic Lymphocytic Leu ...... eukemia Treated with Imatinib.

@en

prefLabel

B-Cell Chronic Lymphocytic Leu ...... eukemia Treated with Imatinib.

@ast

B-Cell Chronic Lymphocytic Leu ...... eukemia Treated with Imatinib.

@en

P1476

B-Cell Chronic Lymphocytic Leu ...... eukemia Treated with Imatinib.

@en

P2093

Anna Czyż

http://www.w3.org/2001/XMLSchema#string

Anna Wache

http://www.w3.org/2001/XMLSchema#string

Maria Lewandowska

http://www.w3.org/2001/XMLSchema#string

Mieczysław Komarnicki

http://www.w3.org/2001/XMLSchema#string

P2860

Computational analysis of the binding specificity of Gleevec to Abl, c-Kit, Lck, and c-Src tyrosine kinases.

Genetic abnormalities in chronic lymphocytic leukemia: where we are and where we go

Acquired chromosomal anomalies in chronic lymphocytic leukemia patients compared with more than 50,000 quasi-normal participants.

Chronic myeloid leukemia: mechanisms of blastic transformation

The role of the JAK2 GGCC haplotype and the TET2 gene in familial myeloproliferative neoplasms

Chronic myeloid leukaemia as a model of disease evolution in human cancer.

MTHFR genetic polymorphisms may contribute to the risk of chronic myelogenous leukemia in adults: a meta-analysis of 12 genetic association studies.

Potential role of Notch signalling in CD34+ chronic myeloid leukaemia cells: cross-talk between Notch and BCR-ABL

Second cancers in patients with chronic lymphocytic leukemia who received frontline fludarabine, cyclophosphamide and rituximab therapy: distribution and clinical outcomes.

Evolution and impact of subclonal mutations in chronic lymphocytic leukemia

P304

9806515

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1155/2016/9806515

http://www.w3.org/2001/XMLSchema#string

P478

2016

http://www.w3.org/2001/XMLSchema#string

P50

Malgorzata Jarmuz-Szymczak

K Lewandowski

M Gniot

Blazej Ratajczak

P577

2016-03-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

297598671

http://www.w3.org/2001/XMLSchema#string

P698

27034682

http://www.w3.org/2001/XMLSchema#string

P921

lymphocyte

chronic myeloid leukemia

P932

4807041

http://www.w3.org/2001/XMLSchema#string